Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
July 1, 2022 — A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.

Treatment Action Group Statement on NYC DOHMH Monkeypox Vaccination Announcement
June 23, 2022 — In response to this morning’s announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group’s Executive Director, Mark Harrington, and TAG HIV Project Director…

Treatment Action Group Mourns Urvashi Vaid, Celebrates Her Life and Legacy
May 17, 2022 — Treatment Action Group (TAG) today mourns the premature loss of transformative LGBTQ and AIDS activist Urvashi Vaid, formerly executive director of the National Gay and Lesbian Task Force (now the National LGBTQ Task Force) at the height of the U.S. AIDS crisis in the late 1980s and early 1990s, and…

World Malaria Day 2022 Long-Acting Technologies Community Advisory Board (LAT-CAB) Statement
May 16, 2022 — As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing 12 countries, vast civil society networks, and people living with and affected by malaira, HIV, tuberculosis, and hepatitis C across the world – in reflection of World Malaria Day on April 25, 2022 – we are shocked and united…

U.S. Government Funded Research Brings Shorter Tuberculosis Treatment Regimens to New York City
May 16, 2022 — We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB).

Joint Statement from Leading HIV/AIDS and Viral Hepatitis Advocates regarding Manufacturer Action on the 340B Drug Pricing Program
April 20, 2022 — A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program:

CROI 2022 TB Round Up
March 22, 2022 — Treatment Action Group welcomes the tuberculosis (TB) data reported at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI). This is a summary of major findings — and TAG’s take on them.

Mourning Paul Farmer, Honoring His Legacy
February 23, 2022 — TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.

TB Vaccine Advocacy Roadmap Calls for Increased EU Funding for TB Vaccine Development
February 16, 2022 — TAG stands proudly alongside the TB community to issue this press statement calling for increasing European funding for TB vaccine development, just before the sixth Global Forum on TB Vaccines convenes in Toulouse, France.